News headlines about Beigene (NASDAQ:BGNE) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Beigene earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.7524927511385 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- Beigene Ltd (BGNE) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- $23.00 Million in Sales Expected for Beigene Ltd (BGNE) This Quarter (americanbankingnews.com)
- BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting – GlobeNewswire (press release) (globenewswire.com)
- Stocks in Focus: Nokia Corporation, (NYSE: NOK), BeiGene, Ltd., (NASDAQ: BGNE) – Stocks In Focus (press release) (nysetradingupdates.com)
- Jane Huang Sells 1,100 Shares of Beigene Ltd (BGNE) Stock (americanbankingnews.com)
Shares of Beigene (NASDAQ:BGNE) traded up $3.46 during trading on Thursday, hitting $96.22. The stock had a trading volume of 412,376 shares, compared to its average volume of 205,782. Beigene has a 1-year low of $26.43 and a 1-year high of $118.95. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.27.
Several equities analysts have weighed in on the company. Maxim Group reaffirmed a “buy” rating and issued a $120.00 target price (up from $77.00) on shares of Beigene in a research report on Thursday, September 28th. Zacks Investment Research downgraded Beigene from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $86.00 target price (up from $43.00) on shares of Beigene in a research report on Tuesday, August 15th. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 target price (up from $58.00) on shares of Beigene in a research report on Tuesday, November 14th. Finally, Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $96.67.
In other news, CEO John Oyler sold 150,957 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Jane Huang sold 1,100 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.00, for a total value of $94,600.00. Following the transaction, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,781,400. The disclosure for this sale can be found here. Over the last three months, insiders have sold 285,399 shares of company stock valued at $23,526,732. Corporate insiders own 19.90% of the company’s stock.
WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/07/beigene-bgne-earns-daily-news-sentiment-rating-of-0-13.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
What are top analysts saying about Beigene Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Beigene Ltd and related companies.